Subscribe

Peter Martin, MD

Articles by Peter Martin, MD

Dr. Martin on the Utility of CAR T-Cell Therapy in High-Risk MCL

ByPeter Martin, MD

April 2nd 2021

Peter Martin, MD, discusses selecting treatment for patients with high-risk mantle cell lymphoma.

Dr. Martin on Potential for CAR T-Cell Therapy in MCL Landscape

ByPeter Martin, MD

September 1st 2017

Peter Martin, MD, assistant professor of medicine in the Division of Hematology/Oncology at Weill Cornell Medical College, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the potential of chimeric antigen receptor (CAR) T-cell therapy in the landscape of mantle cell lymphoma (MCL).

Latest Updated Articles

Uptake of Nononcology Gene Therapy Remains Slow in Hematology
Published: August 16th 2024 | Updated: August 19th 2024
Phase 3 Trial Seeks to Continue Supporting Arsa-Cel Gene Therapy for MLD
Published: March 18th 2024 | Updated: June 3rd 2024
Rapcabtagene Autoleucel Shows Promise for DLBCL in Updated Phase 2 Data
Published: December 7th 2024 | Updated:
Aimee C. Talleur, MD, on Predicting Response and Toxicity to Cell Therapy
Published: December 12th 2022 | Updated:
RPE Cell Therapy Shows Improvements in Early GA With AMD
Published: July 14th 2024 | Updated:
Multi-Characteristic Opsin Gene Therapy for Retinitis Pigmentosa Improves Multiple Measures of Vision
Published: May 18th 2023 | Updated:

Trending on CGTlive®

Top News in Lymphoma Cell Therapy for World Lymphoma Awareness Day 2025

Ultragenyx's Glycogen Storage Disease Gene Therapy DTX401 Continues to Enable Decreases in Reductions in Daily Cornstarch Intake at 96 Weeks

ImmunoLogic, Episode 6: "The Future of Personalized Cancer Vaccines”

© 2025 MJH Life Sciences^®

All rights reserved.